Longport Gains Additional FDA Marketing Clearance

  
    
  
  
    
      Longport, Inc. (OTC PK: LPTI), a medical technology specialist in 
      high-frequency, high-resolution ultrasound imaging, today announced that 
      it had gained additional FDA marketing clearance for its EPISCAN 
      high-resolution ultrasound imaging system.
    
    
      The expanded clearance, which has the FDA reference number K062571, is 
      summarized by the indications of use statement below and is in addition 
      to the FDA clearance previously obtained under reference number K990238. 
      This clearance will enable Longport to directly market for specific 
      clinical applications as described below.
    
    
      “The EPISCAN I-200 high-resolution 
      ultrasound system is a specialized system for imaging the skin and 
      underlying soft tissue. It is intended for use by clinicians, or 
      under the direction of physicians for imaging and analysis in research 
      environments as well as clinical settings including medical / surgical 
      dermatology assessment and diagnosis (aesthetic and therapeutic), 
      plastic / reconstructive surgical planning, wound assessment and 
      management, skin assessment for pressure ulcer detection and prevention 
      and superficial musculoskeletal diagnosis.”
    
    
      Paul Wilson, President of Longport commented. “During 
      2006, Longport’s strategy included obtaining 
      regulatory acceptance, embarking on an expanded clinical study program 
      and the publication of study results, as well as continued research and 
      development to enhance our technological base. This deliberate process 
      for gaining recognition for the use of our technology as well as 
      validating the benefits is necessary to establish commercial markets for 
      our products and gain acceptance for the use of diagnostic ultrasound in 
      markets where imaging technology is not firmly established.”
    
    
      About Longport, Inc.
    
    
      Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology 
      company that specializes in high-resolution ultrasound imaging. After 
      several years and a multimillion dollar investment in the technology, 
      Longport has secured patents, copyrights and FDA permission to market. 
      The Company’s technology has been used to 
      engineer a unique high-resolution ultrasound imaging system. For further 
      information please contact Longport, Inc. at 1-800-289-6863 or visit our 
      website at www.longportinc.com.
    
    
      Forward-looking Information and the Private Securities Litigation 
      Reform Act of 1995
    
    
      Certain statements in this press release, including statements 
      concerning product development milestones and anticipated events, are “forward-looking 
      statements” within the Private Litigation 
      Reform Act of 1995. Forward Looking Statements are based on the 
      opinions and estimates of management at the time the statements are made 
      and are subject to certain risks and uncertainties that could cause 
      actual results to differ materially from those anticipated in the 
      forward-looking statements. The words “believe,” 
      “expect,” “intend,” 
      “anticipate,” 
      variations of such words, and similar expressions identify 
      forward-looking statements, but their absence does not mean that the 
      statement is not forward-looking. These statements are not 
      guarantees of future performance and are subject to certain risks, 
      uncertainties and assumptions that are difficult to predict. Factors 
      that could affect Longport’s actual results 
      include, among others, uncertainties as to the Company’s 
      ability to manage potential problems, delays or anticipated expenses, 
      including problems, delays or expenses involving manufacturing. Readers 
      are cautioned not to place undue reliance upon these forward-looking 
      statements that speak only to the date of this release. Reference 
      is made to Longport’s 2004 annual report on 
      Form 10-K filed with the Securities and Exchange Commission for a more 
      definitive description of such factors. Longport, Inc. undertakes 
      no obligation to update publicly any forward-looking statements to 
      reflect new information, events or circumstances after the date of this 
      release or to reflect the occurrence of unanticipated events.